Andere talen Annexin Pharmaceuticals AB

Aandelen

ANNX

SE0009664154

Beurs gesloten - Nasdaq Stockholm Andere beurzen 17:05:08 02-05-2024			Variatie 5 dagen	Verschil t.o.v. 1 jan (%)
0,308 ^SEK	+2,67%		+11,59%	+18,46%

30/04	Annexin Pharmaceuticals AB (Publ) kondigt Fase II studie aan volledig gerekruteerd met positieve signalen	CI
12/04	Annexin Pharmaceuticals AB (publ) rapporteert resultaten voor het eerste kwartaal eindigend op 31 maart 2024	CI

Andere talen

Krijg toegang tot al het nieuws over alle bedrijven: mis nooit meer een winstgevende beleggingskans!

Gratis inschrijven

BioStock: Annexin's phase II study fully recruited with positive signals	30/04
Annexin Pharmaceuticals AB Announces Phase II Study Fully Recruited with Positive Signals	30/04
Last patient treated in Annexin’s RVO study - promising signals of effect and no safety concerns	25/04
BioStock: Annexin towards completion of phase II study and share issue	18/04
Annexin Pharmaceuticals AB Reports Earnings Results for the First Quarter Ended March 31, 2024	12/04
Annexin resolves on a rights issue of SEK 45.1 million guaranteed to 90 percent, subject to approval by the 2024 Annual General Meeting, which has been decided to be brought forward	28/03
BioStock: Strong start for Annexin in 2024	14/02
Annexin Pharmaceuticals AB Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023	09/02
Update on Annexin´s RVO study confirms promising signals of effect	08/02
Annexin Pharmaceuticals AB Provides Update on RVO Study Confirms Promising Signals of Effect	08/02
Annexin presents at Redeye’s Fight Cancer event on January 24	18/01
Annexin announces outcome of the rights issue and resolves on directed issues to guarantors and lenders	18/12
The subscription period in Annexin Pharmaceuticals’ rights issue begins today	30/11
Annexin Pharmaceuticals publishes prospectus in connection with forthcoming rights issue	28/11
First patients treated with higher dose without adverse events in Annexin's RVO study	23/11
Annexin granted additional patent protection in the US	14/11
Annexin Pharmaceuticals AB Announces Additional Patent Protection in the US	14/11
First patient treated in the second dose group in Annexin's RVO study	25-10-23
First patient treated in the second dose group in Annexin's RVO study	25-10-23
Annexin Pharmaceuticals AB Announces First Patient Treated in the Second Dose Group in RVO Study	25-10-23

Geen resultaten voor deze zoekopdracht

Al het nieuws Aanbevelingen van analisten Belangrijkste gebeurtenissen Insiders Transcripties Persberichten Officiële publicaties Andere talen Ideeën voor de handel MarketScreener-artikels MarketScreener-analyses

Andere talen Annexin Pharmaceuticals AB

Aandelen

ANNX

SE0009664154

Andere talen

Filters